Primary Prevention Hepatocellular Carcinoma by Metformin
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Metformin treatment during 36 months could be associated with decreased risk of HCC
occurrence and liver related death in patients with compensated HCV cirrhosis and
insulinoresistance.
This study is an ancillary of the observational study from the CIRVIR cohort in which more
than 1200 patients with compensated HCV cirrhosis are currently included.
participating centers : 26
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)